Lymphocryptovirus Infections – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23276IDB-L5

Select Item

Empower your strategies with our Lymphocryptovirus Infections – Drugs In Development, 2024 report and make more profitable business decisions.

Lymphocryptovirus infections are caused by a genus of herpesviruses that infect humans and other primates. The most well-known lymphocryptovirus is the Epstein-Barr virus (EBV), which can cause mononucleosis, lymphoma, and nasopharyngeal carcinoma in humans. Lymphocryptovirus infections are usually latent, meaning that the virus remains dormant in the host cells until it is reactivated by stress or immune suppression. Lymphocryptovirus infections can be detected by serological tests or by molecular methods such as polymerase chain reaction (PCR). Lymphocryptovirus infections are widespread among wild bonobos, but the prevalence varies among different populations and habitats. Lymphocryptovirus infections may pose a threat to the conservation of bonobos, as they can increase the risk of developing malignancies or reduce the immune response to other pathogens.

The Lymphocryptovirus Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Lymphocryptovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lymphocryptovirus Infections and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Lymphocryptovirus Infections
Key Targets
· Epstein Barr Virus Envelope Glycoprotein GP350; Epstein Barr Virus Envelope Glycoprotein L; Epstein Barr Nuclear Antigen 1; Epstein Barr Virus Envelope Glycoprotein H; Epstein Barr Virus Glycoprotein 42; DNA Polymerase; Epstein Barr Virus Envelope Glycoprotein B; Programmed Cell Death Protein 1; Tyrosine Protein Kinase JAK1; and Tyrosine Protein Kinase JAK2
Key Mechanisms of Action
· Epstein Barr Nuclear Antigen 1 Inhibitor; DNA Polymerase Inhibitor; Programmed Cell Death Protein 1 Antagonist; Thymidine Kinase Inhibitor; Tyrosine Protein Kinase JAK1 Inhibitor; Tyrosine Protein Kinase JAK2 Inhibitor; CD3 Agonist; Cyclin Dependent Kinase 9 Inhibitor; Cyclin Dependent Kinase 6 Inhibitor; and Cytotoxic T Lymphocyte Protein 4 Antagonist
Key Routes of Administration
· Intravenous; Parenteral; Oral; Intramuscular; Intraperitoneal; Intradermal; Intravenous Drip; and Topical
Key Molecule Types
· Cell Therapy; Gene-Modified Cell Therapy; Small Molecule; Subunit Vaccine; mRNA Vaccine; Monoclonal Antibody; Vaccine; Recombinant Vector Vaccine; Fusion Protein; and Antibody
Major Companies
· Baylor College of Medicine; Atara Biotherapeutics Inc; Children's Research Institute; Moderna Inc; Vironika LLC; ViroStatics SRL; Viracta Therapeutics Inc; Virogin Biotech Ltd; Vernagen Inc; and Valneva SE

Scope

  • Therapeutics in Development: Covering 76 molecules, with 40 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Lymphocryptovirus Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Lymphocryptovirus Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lymphocryptovirus Infections treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AlloVir Inc
Antengene Corp Ltd
Atara Biotherapeutics Inc
Baylor College of Medicine
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Calder Biosciences Inc
Cancer Research UK
Centre National de la Recherche Scientifique
Chengdu WestGene Biopharma Co Ltd
Children's Hospital Los Angeles
Children's National Hospital
Children's National Research Institute
Children's Research Institute
China Immunotech Co Ltd
Citranvi Biosciences LLC
Codiak BioSciences Inc
Dana-Farber Cancer Institute Inc
Dultech Advanced Sciences
Eutilex Co Ltd
Fred Hutchinson Cancer Research Center
Galenbio Ltd
Geneius Biotechnology Inc
George Papanicolaou Hospital
Grid Biosciences Hong Kong Ltd
Helmholtz Center Munich German Research Center for Health and Environment GmbH
iCELL Biotechnology Co Ltd
Immunotech Biopharm Ltd
Incyte Corp
Innovent Biologics Inc
Istituto Giannina Gaslini
Jiangsu Hengrui Medicine Co Ltd
Lion TCR Pte Ltd
Ludwig-Maximilians-University Munich
ManysmarT Therapeutics Inc
Medical College of Wisconsin
Merck & Co Inc
Moderna Inc
Nanjing Gulou Hospital
Nanjing Medical University Hospital 2
Nantes University Hospital
National University of Singapore
NexImmune Inc
Omeros Corp
Oxford Vacmedix UK Ltd
Peking University People's Hospital
QIMR Berghofer Medical Research Institute
Replicate Bioscience Inc
Savoy Pharmaceuticals Inc
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shanghai YaKe Biotechnology Co Ltd
Shenzhen Geno-Immune Medical Institute
Stemirna Therapeutics Ltd
SymBio Pharmaceuticals Ltd
The Chinese University of Hong Kong
The National Institute of Allergy and Infectious Diseases
U.S. National Institutes of Health
University College London
University of Pittsburgh
University of Queensland
University of Texas MD Anderson Cancer Center
University of Toronto
Valneva SE
Vernagen Inc
Viracta Therapeutics Inc
Vironika LLC
ViroStatics SRL
Western Sydney Local Health District (Australia)
Wistar Institute

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Lymphocryptovirus Infections reports
Pharmaceuticals
New
Q2 2026 CRO Activity and Intel Report
$1,870 | July 2026
Pharmaceuticals
New
Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline…
$17,995 | July 2026
Pharmaceuticals
New
Type 2 Diabetes (T2D): Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Lymphocryptovirus Infections – Drugs In Development, 2024 in real time.

  • Access a live Lymphocryptovirus Infections – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more